Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0033774 (pruritus)
 14,546 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The purpose of the present investigation was to study the usefulness of oral treatment of psoriasis with psoralens and longwave ultraviolet light and the possible cytogenetic hazards of this therapy. 8-methoxypsoralen (8-MOP) in doses between 15 and 60 mg orally followed 2 hours later by UVA irradiation of one side of the body gave a healing of the irradiated side in 24 of 40 cases and an improvment in another 11 cases while only one case healed on the side of body that was not irradiated. The most common undesired side effect was pruritus on the irradiated side of the body. The cytogenetic study showed that 8-MOP and UVA treatment of lymphocytes in vitro gives rise to chromosomal aberrations. In a combined in vivo-in vitro study where the lymphocytes had been isolated from a patient 2 hours after intake of 60-80 mg 8-MOP and then irradiated with therapeutic UVA doses, a significant increase in chromosomal aberrations was found. When chromosome analyses were made on the patients whilst the 8-MOP treatment was temporarily withdrawn and when the lymphocytes were not irradiated in vitro, no increased frequency of chromosomal abberations was found on comparison with a group of psoriatic patients receiving dithranol therapy.
 ...
PMID:Treatment of psoriasis with oral psoralens and longwave ultraviolet light. Therapeutic results and cytogenetic hazards. 5 73

Topical applications of a 1.5 percent aqueous solution of 6-aminonicotinamide for four weeks resulted in substantial improvement or complete clearing of plaques of psoriasis in 27 of 34 patients. These results were clearly superior to those that were obtained with the solvent alone. Dermatitis or marked itching occurred in five of 34 patients. Topically applied thionicotinamide also produced improvement or clearing of some psoriatic lesions in an initial screening trial. The toxic hazards of 6-aminonicotinamide to the central nervous system are discussed.
 ...
PMID:Treatment of psoriasis with 6-aminonicotinamide. 12 68

This paper describes the cutaneous side-effects which appeared in 5 patients under Lithium medication for manic-depressive disease: 2 cases with facial and dorsal acne, 1 case with generalized pruritus with burning sensations on the tongue and tumefaction of the lips, 1 case with endogenous generalized psoriasis and 1 case with palmo-plantar hyperkeratosis, ichthyosis and associated with euthyroid goitre. The lithium content of the tissues was assayed by flame spectrophotometry of calcinated biopsy material taken from the epidermis, the dermis and the subcutaneous adipose tissue from 4 of our 5 cases. An experimental investigation was carried out in guinea pigs fed with lithium salts during 6 months. The cation was assayed in samples of epidermis, dermis and perirenal adipose tissue. A study of the accumulation of lithium in epidermal, dermal and adipose tissue is thus added to the studies already published regarding the accumulation of this ion in other tissues.
 ...
PMID:[Cutaneous side-effects of treatment with lithium (author's transl)]. 14 68

Dermatitis occurring as a side effect in psoriatic patients during oral administration of the retinoid acid derivative Ro 10-9359 is described. This so-called retinoid dermatitis exhibits a characteristic disseminated pattern. Sites of predilection are the face, the exterior surface of the upper and the interior surface of the lower arms, the superior thoracic aperture, the back of the hands and the flanks. The lesions present as follicular papules and/or vesicles. The histological picture is that of acute non-specific dermatitis. This retinoid dermatitis was observed in 9 our of 23 patients (39%) treated with Ro 10-9359. Other side effect such as erythema, desquamation, itching and, rarely, a burning sensation showed the same distribution. The characteristic dermatitis, as well as the other side effects mentioned, occur dose-dependently within the normal therapeutic range of Ro 10-9359 for psoriasis (0.5--1 mg/kg bodyweight daily).
 ...
PMID:[Side effects of oral retinoid Ro 10-9359 on the unaffected skin of psoriatic patients: retinoid dermatitis]. 16 14

Fifteen patients with a variety of itching skin diseases (atopic eczema, dermatitis herpetiformis, lichen planus, urticaria and psoriasis) have been studied in the sleep laboratory. Recordings were made of all-night electroencephalogram, electro-oculogram, submental electromyogram, and muscle potentials from both forearms. Bouts of scratching during orthodox (NREM) sleep occurred more frequently in stages 1 and 2 than in stages 3 and 4. The frequency in paradoxial (REM) sleep was close to that in stage 2 sleep. This pattern was similar for all the diseases studied and seems to be related to the physiology of the sleep stages rather than to the skin diseases themselves. The mean duration of the bouts of scratching was not related to the sleep stage in which they started.
 ...
PMID:Further studies of scratching during sleep. 17 5

Twenty-seven patients with psoriasis of the scalp participated in a double-blind, paired comparison study between halcinonide solution (0.1%) and placebo. The therapeutic response was excellent in sixteen patients treated with halcinonide and in one patient treated with placebo. In the comparative evaluation halcinonide was superior in twenty-two patients, the placebo was superior in four patients, and both drugs were equally effective in one patient. There were no adverse reactions due to halcinonide, but one patient experienced pruritus with the placebo solution.
 ...
PMID:Double-blind comparison of halcinonide solution and placebo control in treatment of psoriasis of the scalp. 34 15

A clinical cooperative study involving 14 centers evaluated photochemotherapy (psoralen and high-intensity long-wave ultraviolet light [PUVA]) for psoriasis. Results from 465 patients treated with a PUVA-48 unit (equipped with 48 high-intensity UVA bulbs) and 110 patients treated with a PUVA-64 unit (equipped with 64 high-intensity UVA bulbs) confirmed the effectiveness of photochemotherapy for psoriasis. Clearing of psoriasis occurred in 85% of patients on PUVA-48 therapy. Mean number of treatments, joules per square centimeter, to clear, and total joules at clearing were similar to other reported trials. The plateau method of clearing resulted in lower joules per square centimeter at clearing, total joules per square centimeter, and number of treatments than the nonplateau method. Maintenance therapy groups were mainly M1 (once weekly) or M4 (no treatment for more than 60 days). No meaningful laboratory abnormalities were detected and ophthalmologic examinations showed a few abnormal results following PUVA. Short-term side effects were mainly erythema, nausea, and pruritus. The effectiveness and short-term safety of PUVA for psoriasis has now been confirmed by a second large cooperative study.
 ...
PMID:Photochemotherapy for psoriasis. A clinical cooperative study of PUVA-48 and PUVA-64. 37 39

Twenty eight patients with various dermatological conditions were treated orally with the new aromatic derivate of retinoic acid, Ro 10-9359. The initial average dose was 48,3 mg/day and the maintenance dose was 26,6 mg/day. Duration of treatment ranged between 3 to 6 months. Evolution of erythema, infiltration and hyperkeratosis showed changes statistically significant (p < 0,05) and excellent to good results were obtained in 23 out of the 28 treated patients. On the basis of this study it is concluded that Ro 10-9359 is a promising drug for the treatment of several skin diseases, specially ichthyosis, Darier's disease, oral lichen planus, erythrokeratoderma variabilis and psoriasis. No serious side effects were reported; dryness of the lips, scaling of palms and soles, pruritus and thinning of the skin were the most common. In no case treatment was discontinued due to side effects. Laboratory controls did not show deviations from the normal values.
 ...
PMID:[Oral treatment of various dermatosis with the aromatic derivative of retinoic acid Ro 10-9359]. 39 25

In most cases the ano-cutaneous clinical symptoms correlated to diseases of the gastro-intestinal tract are not specific (erythema, itching, wounds or scarring). However in the following diseases occasional dermatological lesions may directly contribute to their diagnosis: in Crohn's disease, tuberculosis of bowel, chronic entamoebiasis and bilharziosis, the skin lesions of the anal area have the same histological structure as the gut lesions. Perianal fistulas and ulcers are frequent in Crohn's disease especially if there is a colonic and rectal spreading; they respond badly to steroid therapy and are often correlated with a worse prognosis. Perianal specific lesions occur often in oxyuriasis in children, in candidiasis of the digestive tract, in systemic aphthosis and in some malignancies. In other gastro-intestinal disturbances, the dermatological and features are less specific and can only be suggestive: iatrogenic and microbial diarrheas, side-effects of laxatives, proctological diseases. It has to be emphasized that pruritus ani is only induced by deeper lesions when they spread to the perianal skin. In proctological practice, contact dermatitis by sensitivity to anaesthetics or suppository balsams (Peruvian balsam), itching or burning atrophy by topical steroid abuse, non-diagnosed fungal (candidiasis), bacterial (erythrasma) or psoriatic intertrigos (flexural psoriasis) may sometimes explain the failure of therapy.
 ...
PMID:[Anal symptoms of gastro-intestinal diseases]. 48 13

5-Methoxypsoralen (5-MOP, Bergapten) was evaluated as a potential photosensitizing drug in oral photochemotherapy of psoriasis. Treatment results indicate that (1) 5-MOP is as effective as, and in high doses more effective than, 8-methoxypsoralen in clearing psoriatic lesions; (2) therapeutic doses of 5-MOP do not lead to erythema; the acute side-effects of 8-MOP PUVA therapy--erythema, blistering, pruritus--are thus avoided; (3) even high doses of 5-MOP are not followed by nausea. 5-MOP PUVA therapy thus represents a real alternative to 8-MOP PUVA, its advantages over 8-MOP PUVA being greater safety and patient acceptance.
 ...
PMID:5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis. 50 4


1 2 3 4 5 6 7 8 9 10 Next >>